This study aimed to explore the long-term outcomes of CT-guided radioactive iodine-125 (I-125) seed implantation (RISI) for recurrent desmoid tumor. A multicenter retrospective study reviewed 38 recurrent desmoid tumor patients receiving RISI from July 2013 to July 2021.The clinical outcomes including overall response rate (ORR), disease control rate (DCR), local control time (LCT), overall survival (OS), adverse events (AEs), and symptom relief rate were statistically assessed.
Desmoid tumor was characterized by a high potential of recurrence even following initial definitive treatment. There were considerable controversies regarding the management of recurrent desmoid tumor. This study aimed to explore the long-term outcomes of CT-guided radioactive iodine-125 (I-125) seed implantation (RISI) for recurrent desmoid tumor. 38 patients, diagnosed with recurrent desmoid tumor, undergoing RISI in 3 different centers including Peking University Third Hospital, First Affiliated Hospital of the Army Medical University, and Shengli Oilfield Central Hospital from July 2013 to July 2021 were reviewed consecutively. The clinical outcomes including overall response rate (ORR), disease control rate (DCR), local control time (LCT), overall survival (OS), adverse events (AEs), and symptom relief rate were statistically assessed.
Study Type
OBSERVATIONAL
Enrollment
38
The CT-guided radioactive iodine-125 seed implantation procedure mainly consisted of preoperative treatment planning, intraoperative seed implantation and postoperative dosimetric evaluation. All procedures were performed as per relevant guidelines and regulations.
Peking University Third Hospital
Beijing, Beijing Municipality, China
Local control time (LCT)
LCT was defined as the time from seed implantation to local progression
Time frame: 8 years
objective response rate (ORR)
ORR was calculated from patients achieving CR and PR
Time frame: 6 months
disease control rate (DCR)
DCR was likewise calculated from the patients of CR, PR and SD.
Time frame: 6 months
overall survival (OS)
OS was defined as the time from RISI to death from any cause
Time frame: 8 years
adverse events (AEs)
The AEs were evaluated as per Radiation Therapy Oncology Group (RTOG) guidelines.
Time frame: 8 years
symptom relief rate
symptom relief rate was calculated from the patients achieving relief after treatment.
Time frame: 8 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.